Furthermore, a recent study shows that activities of c‐Myc and AR pathways are significantly correlated in prostate cancer, while c‐Myc depletion leads to decreased expression of full‐length AR, as well as of several AR splice variants involved in AR‐targeted therapy resistance (Bai et al, 2019). This evidence concerns the gene AR and prostate carcinoma.